By Anthony O. Goriainoff

AstraZeneca said Thursday that it was discontinuing the brazikumab inflammatory bowel disease development program after reviewing its development timeline as well as the context "of a competitive landscape that has continued to evolve."

The Anglo-Swedish pharma giant said the timeline had been hurt by delays that couldn't be mitigated following global events and that no safety concerns were identified for patients in these trials.

The company said that AbbVie had partly funded the program and that this funding will now stop.

AstraZeneca said that the program was investigating an anti IL-23 monoclonal antibody for the treatment of Crohn's disease and ulcerative colitis.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

(END) Dow Jones Newswires

June 01, 2023 02:44 ET (06:44 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Astrazeneca